Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.43 |
| ▸ | RXRB | P28702 | 6/20 | 0.43 |
| ▸ | RXRG | P48443 | 6/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | RARB | P10826 | 3/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8308767 | 0.84 | RXRA (0.36) | RXRARXRBRXRGKDM1ARARB | |
| SCHEMBL6939291 | 0.84 | RXRA (0.36) | RXRARXRBRXRGKDM1ARARB | |
| SCHEMBL15717279 | 0.79 | RXRA (0.41) | RXRARXRBRXRGPRKCDKDM1A | |
| SCHEMBL21730005 | 0.79 | RXRA (0.44) | RXRARXRBRXRGPRKCD | |
| SCHEMBL22589962 | 0.79 | ESR1 (0.35) | RXRARXRBRXRGPRKCDKDM1A | |
| SCHEMBL9628848 | 0.78 | RXRA (0.37) | RXRARXRBRXRGPRKCDKDM1A | |
| SCHEMBL11599145 | 0.78 | RXRA (0.42) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL5646023 | 0.75 | RXRA (0.44) | RXRARXRBRXRGKDM1A | |
| SCHEMBL31106547 | 0.75 | RXRA (0.44) | RXRARXRBRXRGKDM1A | |
| SCHEMBL5706327 | 0.75 | RXRA (0.51) | RXRARXRBRXRGPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| CN-1173497-A | Heterocycle-containing carbonic acid derivatives | EISAI CO LTD (JP) | 1998-02-18 | — | — | CN | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0638071-B1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR) | EISAI CO LTD (JP) | 1997-04-09 | — | — | EP | disclosed |
| US-5612356-A | RETINOID ANTAGONISTS | EISAI CO., LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
| EP-0638071-A1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR). | EISAI CO LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| CN-1094052-A | Heterocyclic ring-containing carbonic acid derivatives | EISAI CO LTD (JP) | 1994-10-26 | — | — | CN | disclosed |
| WO-1994014777-A1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR) | EISAI CO., LTD. (JP) | 1994-07-07 | — | — | WO | disclosed |